| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8442457 | European Journal of Cancer | 2015 | 8 Pages |
Abstract
Lapatinib showed insufficient activity in HER2-amplified pretreated advanced GC. The safety profile of LAP or LAPÂ +Â CAP was as expected with some more toxicity in the combination arm. (ClinicalTrials.gov Identifier, NCT01145404).
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Sylvie Lorenzen, Jorge Riera Knorrenschild, Georg-Martin Haag, Michael Pohl, Peter Thuss-Patience, Florian Bassermann, Ulrike Helbig, Florian WeiÃinger, Elisabeth Schnoy, Klaus Becker, Gertraud Stocker, Josef Rüschoff, Andreas Eisenmenger,